You are currently viewing our desktop site, do you want to download our app instead?
Moneyweb Android App Moneyweb iOS App Moneyweb Mobile Web App

NEW SENS search and JSE share prices

More about the app

Aspen to make Covid-19 vaccine candidate

Deal with Johnson & Johnson could see the potential vaccine made in Port Elizabeth.
Aspen's Port Elizabeth facility could soon be making a Covid-19 vaccine candidate. Image: Supplied

Aspen Pharmacare’s share price rallied as high as 4% to R109.90 on news that it has entered into a preliminary agreement with Johnson & Johnson to manufacture its Covid-19 vaccine candidate.

The mooted deal, announced in a trading update on Monday, will see Aspen work with the Johnson & Johnson owned Janssen Pharmaceuticals and Janssen Pharmaceutica NV to make their Covid-19 vaccine candidate, Ad26.COV2-S.

The vaccine candidate is currently undergoing clinical trials, and Aspen will “perform formulation, filling and secondary packaging of the vaccine for supply to Johnson & Johnson.”

Aspen On The Rise

Aspen says it’s not a done deal yet as it is still “subject to the successful completion of the relevant technology transfer activities and finalisation of certain commercial manufacturing terms.”

If it does go ahead, manufacturing will take place at its facility in Port Elizabeth.

“Aspen has invested in excess of R3 billion in the facility containing the high technology equipment and systems that will be used to manufacture state-of-the-art sterile drugs and vaccines, packaged into vials, ampoules and pre-filled syringes.”

Aspen says the production area where the vaccine candidate will be manufactured has the capacity to produce more than 300 million doses per annum. The facility is also accredited by a range of international regulatory authorities and provides medicines to both the domestic and international markets.

The facility was part of the first flagship investments announced at the president’s inaugural South African Investment Conference.

Please consider contributing as little as R20 in appreciation of our quality independent financial journalism.

AUTHOR PROFILE

COMMENTS   10

Sort by:
  • Oldest first
  • Newest first
  • Top voted

You must be signed in to comment.

SIGN IN SIGN UP

The scary thing about this virus is that some patients who recover are left with seemingly permanent health issues.

I think you’re right. Just as scary is how many people there are who still feel it’s either a hoax or that it’s nothing more than just a common / typical flu. Their ignorance / stupidity has not only endangered many others, it will also prolong the time it will take to get things under control

Clever Saad! …Looks like you out to save and grow your company!

This is the difference between a CEO who is a founder of a company and a CEO who runs a company without any grass roots to the company.

Aspen is doing a fantastic job of showing the rest of the world how advanced we are as a country in many fields.

The rest of the world should be paying more attention to investing in SA than what they currently are.

Share is rocketing today 🙂

Interesting. Testing Africa first then?

This is brilliant and shows you how dynamic South Africans are and How Dynamic South Africa is. We can export the vaccine throughout the world. Huge vote of confidence in South Africa! Brilliant brilliant Brilliant.

The Aspen share would probably be a lot higher if it were not listed on the JSE.

Imagine this share listed in the US Dow Jones?

I’ll wait for 56 million other suckers to be vaccinated, before deciding

And this considering the terrible H1N1 vaccine deaths, in the hundreds of thousands

nEVER TRUST j&j since baby powder causing cancer

End of comments.

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR

Podcasts

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / LISTEN LIVE SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us: